We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The European Commission is suspending sales and distribution of 700 formulations of more than four dozen generic drugs after determining that the bioequivalence testing on which their approvals were based included manipulated echocardiogram data. Read More
For the third time in less than a week, AstraZeneca has entered into a deal to boost its cancer drug pipeline, this time via a $727.5 million licensing and collaboration agreement with Inovio Pharmaceuticals to develop DNA-based immunotherapies. Read More
The Department of Justice is looking into Allergan’s pricing of certain generic drugs as part of a larger federal probe into rising generic prices. Read More
Amarin Pharmaceuticals has a constitutional right to promote its cholesterol-lowering drug Vascepa for an off-label use as long as the communication is truthful and not misleading, a New York federal judge ruled Friday — dealing a blow to FDA efforts to prevent off-label drug promotion. Read More